{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '9.4.7', 'Pharmacokinetic/Pharmacodynamic Analyses', '9.4.7.1', 'Derivation of Pharmacokinetic Parameters', 'The PK parameters will be derived using non-compartmental methods using the PK analysis set.', 'The actual sampling times will be used in the PK parameter calculations. Further details of PK', 'analysis, data handling, analysis procedures, and data reporting will be detailed in the SAP.', 'The following PK parameters will be determined for ANB019:', 'Maximum observed concentration (Cmax).', 'Time to maximum observed concentration (Tmax).', 'Area under the curve (AUC).', 'Additional PK parameters may be determined if deemed appropriate.', '9.4.7.2', 'Pharmacokinetic Concentration Data Analysis', 'A subject listing of all concentration-time data following study drug administration will be', 'presented by subject and scheduled sample collection time.', 'Concentration data of ANB019 will be summarized by route/day and nominal time point using', 'the number of observations (n), arithmetic mean, SD, coefficient of variation (CV), minimum,', 'median, maximum, and geometric mean.', 'Graphs for mean concentration-time data following IV administration will be presented.', 'Individual subject plots will also be presented. Other presentations of data may be added at the', 'discretion of the PK scientist, as appropriate, and will be described in detail in the SAP.', '9.4.7.3', 'Pharmacokinetic Parameter Data Analysis', 'All PK parameters will be summarized using n, arithmetic mean, SD, CV, minimum, median,', 'maximum, geometric mean, and geometric CV, with the exception of Tmax, which will be', 'reported with n, minimum, median, and maximum only.', 'Graphs of parameters may be added at the discretion of the PK scientist, as appropriate, and will', 'be described in detail in the SAP.', '9.4.8', 'Exploratory Biomarker Analyses', 'Observed and change from Baseline for circulating biomarkers will be listed and summarized', 'descriptively by nominal time point and treatment using the Safety Analysis Set. Baseline will be', 'the last assessment before study treatment administration.', 'The relationship between ANB019 concentrations and biomarker endpoints will be explored', 'graphically.', '29 October 2019', '53']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Skin biomarker analysis may be performed by additional third party (eg, a university', 'Investigator) designated by the Sponsor.', '9.4.9', 'Missing Data', 'Missing data handling and possible sensitivity analysis will be described in the SAP.', '9.5', 'Interim and Final Analyses', 'An interim analysis will be performed when approximately 50% of subjects have completed their', 'Week 4 visit or when at least 2 subjects have reached 16 weeks postdosing. The interim analysis', 'will assess primary efficacy and all safety data. Data from interim analyses might be used as a', 'guideline for possible protocol modifications and planning of future clinical studies.', '29 October 2019', '54']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '10.0 REFERENCES', 'ANB019-001, AnaptysBio, San Diego, CA. A Double-Blind, Randomized, Placebo-Controlled,', 'Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the', 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects', 'and Psoriasis Patients. Clinical Study Report; 22 June 2018.', 'Augey F, Renaudier P, and Nicolas J-F. Generalized pustular psoriasis (Zumbusch): a French', 'epidemiological survey. Eur J Dermatol. 2006;16(6):669-73.', 'Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the IL-36 Pathway for the Treatment of', 'Generalized Pustular Psoriasis. N Engl J Med 2019; 380:(10).', 'Benjegerders K, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and', 'current treatment perspectives. Psoriasis (Auckl). 2016 Sep 12;6:131-144.', 'Capon F. IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg? J Invest', 'Dermatol. 2013;133(11):2503-4.', 'Dubey JP, Markovits JE, and Killary KA. Cryptosporidim muris-like infection in stomach of', 'cynomolgus monkeys (Macaca Fascicularis). Vet Pathol 2002;39(3):363-71.', 'Fagerland, M. W., Hosmer, D. W., and Bofin, A. M. (2008). \"Multinomial Goodness-of-Fit', 'Tests for Logistic Regression Models.\" Statistics in Medicine 27:4238-4253.', 'Farthing MJ. Treatment options for the eradication of intestinal protozoa. Nat. Rev. Gastroent.', 'Hepat. 2006;3:436-45.', 'Farooq M, Nakai H, Fujimoto A, Fujikawa H, Matsuyama A, Kariya N, et al. Mutation analysis', 'of the IL36RN gene in 14 Japanese subjects with generalized pustular psoriasis. Hum. Mutat.', '2013;34:176-83.', 'Finlay AY, Kahn GK. Dermatology Life Quality Index (DLQI): A simple practical measure for', 'routine clinical use. Clinical and Experimental Dermatology. 1994;19:210-6.', 'Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. 1978;157(4):238-', '44.', 'Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of', 'secukinumab in patients with generalized pustular psoriasis: A 52 week analysis from phase 3', 'open-label multicenter Japanese study. The Journal of Dermatology. 2016;43:1011-17. -', 'Jordan C, Cao L, Roberson E, Pierson K, Yang CF, Joyce CE, et al. PSORS2 Is Due to', 'Mutations in CARD14. The American J of Human Genetics. 2012;90:784-95.', '29 October 2019', '55']\n\n###\n\n", "completion": "END"}